Fluoroquinolone Anti-infective Compositions for Mixed Pathogen Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for infections, especially those caused by mixed types of microorganisms, often face delays in effectiveness, leading to increased risks of complications, particularly in vulnerable patients, due to the emergence of antibiotic-resistant bacterial strains and unclear etiology at presentation.
Innovation Solution
Pharmaceutical compositions comprising a fluoroquinolone carboxylic acid or its derivative, in combination with an additional anti-infective medicament, such as antiviral or antifungal agents, are administered to inhibit the growth or survival of mixed microorganisms causing infections in the ear, respiratory system, or eye, providing rapid therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a single antibiotic is used to treat infections, then the treatment is simple and cost-effective, but it becomes ineffective against antibiotic-resistant bacterial strains and mixed microorganism infections
Solution Approach 1:
The patent combines multiple anti-infective agents with different mechanisms of action into a single pharmaceutical composition. This merging approach allows the treatment to effectively target mixed microorganism infections and antibiotic-resistant strains while maintaining ease of administration as a single formulation.
Solution Approach 2:
The pharmaceutical composition is designed with multi-functionality to treat various types of infections simultaneously - bacterial, viral, and fungal. The composition includes agents that target different pathogen types, making it a universal treatment solution for complex infections that may involve multiple microorganism types.
2Measurement precision
If treatment is delayed to determine etiology, then diagnostic accuracy improves, but patient outcomes worsen due to increased risk of complications
Solution Approach 1:
The patent employs a preliminary action strategy by providing empiric therapy that covers multiple potential pathogens before definitive diagnosis is established. The broad-spectrum anti-infective composition is administered immediately upon suspicion of infection, preventing complications while awaiting diagnostic results.
Solution Approach 2:
The treatment approach changes the parameter of therapeutic coverage from narrow (single pathogen target) to broad (multiple pathogen types). By using a composition that targets bacteria, viruses, and fungi simultaneously, the treatment remains effective across different etiologies without requiring immediate diagnostic precision.
3Reliability
If broad-spectrum anti-infectives are used empirically, then treatment effectiveness improves immediately, but development of resistance to multiple agents increases
Solution Approach 1:
The patent uses synergistic combinations of anti-infective agents where each component acts as an intermediary that enhances the effectiveness of the others. This synergistic interaction allows lower doses of each individual agent to be used, reducing the selective pressure for resistance development while maintaining broad-spectrum effectiveness.
Data Source
AI summary
Compositions for treating, reducing, ameliorating, or preventing infections comprise a fluoroquinolone having Formulae I-VIII and an additional anti-infective agent. Methods for treating, reducing, ameliorating, or preventing such infection use such compositions. Such compositions and methods can be effective against mixed types of pathogens including certain antibiotic-resistant microbial pathogens found in such infections.